NCT06581497View on ClinicalTrials.gov

ICIs with and Without MWA in Advanced Hepatocellular Carcinoma

Active, not recruitingOBSERVATIONAL
Enrollment

52

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

January 1, 2025

Study Completion Date

January 1, 2025

Conditions
HCCTherapy Adverse Effect
Interventions
DRUG

ICIs

ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines.

PROCEDURE

ICIs+MWA

ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines. All patients, except for those enrolled in ICIs, should also undergo MWA treatment.

Trial Locations (1)

641000

The First People's Hospital of Neijiang City, Neijiang

All Listed Sponsors
lead

The First People's Hospital of Neijiang

OTHER